Detection of HER2 and Topo 2 in breast cancers: Comparison between MLPA and FISH approaches

Journal of Clinical Pathology

Volumn 65, Issue 2, 2012, Pages 183-185

  Bravaccini, Sara ^a   Rengucci, Claudia ^a   Medri, Laura ^b   Zoli, Wainer ^a   Silvestrini, Rosella ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; TOPO 2 GENE;

BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 84856120120     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200342     Document Type: Article

References (12)

1. Järvinen TA, Liu ET. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003;78:299-311. (Pubitemid 36543210)
2. Beser AR, Tuzlali S, Guzey D, et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 2007;13:180-5. (Pubitemid 350221219)
3. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003;14:314-19. (Pubitemid 37521861)
4. Villman K, Stahl E, Liljegren G, et al. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 2002;15: 486-91. (Pubitemid 34521397)
5. Manna Edel F, Teixeira LC, Alvarenga M. Association between immunohistochemical expression of topoisomerase IIalpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer. Tumori 2006;92:221-9.
6. Harris LN, Liotcheva V, Broadwater G, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001;19:1698-706. (Pubitemid 32230870)
7. Park K, Kim J, Lim S, et al. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003;16:937-43. (Pubitemid 37152024)
8. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
9. Romero A, Martin M, Cheang MC, et al. Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol 2011;178:1453-60.
10. Schindlbeck C, Mayr D, Olivier C, et al. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol 2010;136:1029-37.
11. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
12. Moelans CB, de Weger RA, van Blokland MT, et al. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol 2010;23:61-70.